Use of Recombinant Human Deoxyribonuclease I in Primary Ciliary Dyskinesia Bronchiectasis—A Real Life Pilot Study
Medical Sciences · 2026
DOI: 10.3390/medsci14010133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, 2026. Verfasst von Moshe Heching und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Department, Beilinson Hospital, Rabin Medical Center, Petach Tikva 4941492, Israel. Hauptthemen laut MEDLINE: Bronchiectasis, Deoxyribonuclease I, Recombinant Proteins, Kartagener Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Recombinant human deoxyribonuclease I (rhDNase) cleaves DNA in mucus, facilitating increased mucociliary clearance of purulent sputum. In cystic fibrosis (CF), rhDNase improves pulmonary function and decreases exacerbations. Conversely, rhDNase use in non-CF bronchiectasis (NCFB) patients has not yielded similarly effective results. We explored the safety and feasibility of rhDNase in patients with bronchiectasis due to primary ciliary dyskinesia (PCD).
Methods
In this real-life pilot study, patients with PCD received rhDNase to treat viscous mucus. We compared pulmonary function tests and pulmonary exacerbations for these patients over six months of use of rhDNase.
Results
Eight PCD patients with symptomatic bronchiectasis commenced use of rhDNase at variable dosing (ranging from at least twice weekly to a full 2.5 mg dose daily). Over a six-month period, pulmonary function tests, as measured by mean FVC and FEV1, remained relatively stable compared to prior to commencing rhDNase. Mean pulmonary exacerbations decreased from 3.1 to 2.3 in the six-month period after commencing rhDNase, as compared to the six-month period prior to rhDNase.
Conclusions
Use of rhDNase in PCD patients was safe and did not adversely impact lung function or increase pulmonary exacerbations, in contrast to earlier trial results in NCFB patients with heterogeneous etiologies. Further clinical data is required to identify the population of PCD patients who can benefit from rhDNase, as well as the appropriate dosing and timing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary Department, Beilinson Hospital, Rabin Medical Center, Petach Tikva 4941492, Israel.
- Gray Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
ORCID-Profile: Moshe Heching, Eviatar Naamany
Zitieren
APA
Heching, M., Slomianksy, L., Naamany, E., Weinberg, J., & Kramer, M. R. (2026). Use of Recombinant Human Deoxyribonuclease I in Primary Ciliary Dyskinesia Bronchiectasis—A Real Life Pilot Study. Medical Sciences. https://doi.org/10.3390/medsci14010133
Vancouver
Heching M, Slomianksy L, Naamany E, Weinberg J, Kramer MR. Use of Recombinant Human Deoxyribonuclease I in Primary Ciliary Dyskinesia Bronchiectasis—A Real Life Pilot Study. Medical Sciences. 2026. doi:10.3390/medsci14010133
BibTeX
@article{Heching2026,
author = {Heching, Moshe and Slomianksy, Liora and Naamany, Eviatar and Weinberg, Joel and Kramer, Mordechai R},
title = {Use of Recombinant Human Deoxyribonuclease I in Primary Ciliary Dyskinesia Bronchiectasis—A Real Life Pilot Study},
journal = {Medical Sciences},
year = {2026},
doi = {10.3390/medsci14010133}
}
EUVIMED